Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL - European Medical Journal

Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL

Hematology

In a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), and monoclonal anti-CD20 antibody, rituximab, showed a tolerable safety profile and induced deep and durable responses, with 41% of patients achieving complete response (CR).

Presented by Andrew Roberts, MB BS, PhD, FRCPA, FRACP, Royal Melbourne Hospital, Melbourne, Australia, at the 20th Congress of the European Hematology Association (EHA).

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now